Cyfuse Biomedical K.K. (JP:4892)

:4892

4892

Cyfuse Biomedical K.K.

RESEARCH TOOLSreports

Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥516.00 - ¥1,068.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)50.89K

Market Cap

¥6.27B

Enterprise Value¥3.56B

Total Cash (Recent Filing)¥2.70B

Total Debt (Recent Filing)¥766.00M

Price to Earnings (P/E)―

Beta0.63

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-12.09

Shares Outstanding9,970,400

10 Day Avg. Volume43,580

30 Day Avg. Volume50,893

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Bio-3D Printing TechCyfuse's scaffold-free Bio-3D Printer and Kenzan method represent a distinctive platform technology in regenerative medicine. As a core proprietary capability, it creates a durable technical barrier, underpins product development and research collaborations, and supports long-term differentiation.

Sharp Revenue Rebound And Positive Gross MarginA large 2025 revenue rebound paired with a positive ~34% gross margin indicates recovering demand and economically viable unit production. If sustained, revenue growth with maintained gross margins improves the prospects of absorbing fixed costs and moving toward scalable operations over months.

Manageable Leverage And Sizable Equity BaseDebt-to-equity below 0.5 and a sizable equity base provide financial flexibility relative to peers. Manageable leverage reduces immediate refinancing pressure and, together with growing assets, supports the company’s ability to fund R&D and operational needs while pursuing commercialization over the medium term.

Bears Say

Persistent Negative Cash FlowOperating and free cash flows remain deeply negative, forcing reliance on external capital to sustain operations. Continued cash burn limits runway, risks dilution or costly financing, and constrains the company’s ability to scale activities or invest in commercialization without securing durable funding sources.

Deep Unprofitability And Unscalable Cost StructureExtremely negative EBIT and net margins show costs far exceed revenues, reflecting an unscalable cost base. Persistent multi-year losses indicate structural issues in converting revenue into profitability, posing a long-term risk until cost structure or revenue mix materially improves.

Rising Debt Vs Prior YearMaterial year-over-year debt growth raises financing and solvency risk, particularly given ongoing negative cash flow and losses. Higher leverage can increase interest burdens and reduce strategic flexibility, making the firm more vulnerable if revenue momentum falters or capital markets tighten.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥516.00 and its highest was ¥1068.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥6.27B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is May 20, 2026 which is in 29 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on Feb 13, 2026. The company reported -¥12.09 earnings per share for the quarter, missing the consensus estimate of N/A by -¥12.09.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 9,970,400 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥12.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.277%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.